Advancing care through genomics and immune checkpoint blockade
Crossref DOI link: https://doi.org/10.1038/nrurol.2017.199
Published Online: 2017-11-28
Published Print: 2018-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Galsky, Matthew D.
Text and Data Mining valid from 2017-11-28
Article History
First Online: 28 November 2017
Competing interests
: M.D.G. is a member of the advisory boards of AstraZeneca, Bristol-Myers Squibb (BMS), Genentech, Inovio, Merck, and Merck Serono.